All Updates

All Updates

icon
Filter
Partnerships
Pluristyx and Humacyte enter partnership to develop treatments for insulin-dependant and type 1 diabetes
Human Gene Editing
Jul 9, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Human Gene Editing

Human Gene Editing

Jul 9, 2024

Pluristyx and Humacyte enter partnership to develop treatments for insulin-dependant and type 1 diabetes

Partnerships

  • Cell therapy technology provider Pluristyx and biotechnology company Humacyte have entered an agreement to develop advanced cellular treatments for type 1 diabetes.

  • According to the agreement, Humacyte has been granted rights to use Pluristyx’s PluriBank cell lines in its BioVascular Pancreas development program. The program aims to combine Humacyte’s Acellular Tissue Engineered Vessel (ATEV) with insulin-producing cells derived from Pluristyx’s best-in-class iPSC lines to create a potential cure for insulin-dependent diabetes and for the treatment of type 1 diabetes.

  • Pluristyx is a biotechnology company that advances cellular therapies through innovative tools and technologies. The company specializes in providing induced pluripotent stem cells (iPSCs) and related expertise to accelerate the development and commercialization of cellular therapeutics. It offers a range of products and services, including the proprietary PluriFreeze cryopreservation media, clinical-grade iPSCs, and the panCELLa platform, which includes technologies such as the FailSafe safety switch and iACT Stealth Cells for immune evasion, to increase the efficiency of the development process.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.